Hyphens Pharma International バランスシートの健全性

財務の健全性基準チェック /56

Hyphens Pharma Internationalの総株主資本はSGD69.2M 、総負債はSGD4.0Mで、負債比率は5.7%となります。総資産と総負債はそれぞれSGD131.8MとSGD62.6Mです。 Hyphens Pharma Internationalの EBIT はSGD15.2Mで、利息カバレッジ比率-800.4です。現金および短期投資はSGD17.9Mです。

主要情報

5.7%

負債資本比率

S$3.96m

負債

インタレスト・カバレッジ・レシオ	-800.4x
現金	S$17.92m
エクイティ	S$69.16m
負債合計	S$62.59m
総資産	S$131.76m

財務の健全性に関する最新情報

更新なし

Recent updates

財務状況分析

短期負債: 1J5の短期資産 ( SGD101.6M ) が短期負債 ( SGD57.7M ) を超えています。

長期負債: 1J5の短期資産 ( SGD101.6M ) が長期負債 ( SGD4.9M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 1J5総負債よりも多くの現金を保有しています。

負債の削減: 1J5の負債対資本比率は、過去 5 年間で1.1%から5.7%に増加しました。

債務返済能力: 1J5の負債は営業キャッシュフローによって十分にカバーされています ( 75.6% )。

インタレストカバレッジ: 1J5支払う利息よりも稼ぐ利息の方が多いので、利息支払いの補償は問題になりません。

Hyphens Pharma International バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Recent updates

Hyphens Pharma International Limited Launches Ceradan Advanced Hand Balm, Specially Designed for Hand Eczema

Price target increased by 7.1% to S$0.38

First quarter 2024 earnings released

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023

Final dividend of S$0.0086 announced

Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024

Consensus revenue estimates increase by 10%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Third quarter 2023 earnings released

Price target decreased by 10% to S$0.34

Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023

Second quarter 2023 earnings released

Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer

Price target decreased by 8.9% to S$0.39

Now 23% undervalued after recent price drop

Upcoming dividend of S$0.011 per share at 3.3% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021)

Hyphens Pharma International Limited Launches its New Product, Meradan® Cream ("Meradan®") in Indonesia

Price target increased to S$0.41

Insufficient new directors

Price target increased to S$0.41

Consensus EPS estimates increase by 12%

Second quarter 2022 earnings released

Insufficient new directors

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022

Price target decreased to S$0.35

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022

Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to S$0.35

Third quarter 2021 earnings released: EPS S$0.004 (vs S$0.003 in 3Q 2020)

First quarter 2021 earnings released: EPS S$0.007 (vs S$0.007 in 1Q 2020)

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Revenue and earnings miss expectations

Hyphens Pharma International Limited Appoints Exclusive Distributor in South Korea for Tdf Fairence T-Complex

New 90-day low: S$0.32

Price target lowered to S$0.38

New 90-day low: S$0.34

Hyphens Pharma International Limited Announces Board Changes

Analysts update estimates

First half earnings released

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /56